We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 992

CMS Finalizes Long-Awaited Covered Outpatient Drug Rule
  • Foley & Lardner LLP
  • USA
  • February 8 2016

The Centers for Medicare & Medicaid Services (“CMS”) recently issued a final rule implementing provisions of the Patient Protection and Affordable


Data Transmission, Personalized Medicine, and Privacy
  • Foley & Lardner LLP
  • European Union, USA
  • February 5 2016

Health care analytics make use of patient data to inform treatment decisions and is increasingly moving front and center in personalized medicine


Purdue OxyContin Patents Invalid Despite Stemming From Discovery Of Source Of Toxic Impurity
  • Foley & Lardner LLP
  • USA
  • February 2 2016

In Purdue Pharma L.P. v. Epic Pharma LLC, the Federal Circuit affirmed the district court decision holding four OxyContin patents invalid as obvious


Split Federal Circuit Upholds Constitutionality of Single PTAB Panels Rendering Both Institution & Final Written Decisions
  • Foley & Lardner LLP
  • USA
  • January 29 2016

On January 13, 2016, the Federal Circuit affirmed the decision of the PTAB in Ethicon Endo-Surgery, Inc. v. Covidien LP, IPR2013-00209, that all of


8 Tips for Navigating New Wisconsin Telemedicine Rules
  • Foley & Lardner LLP
  • USA
  • January 26 2016

The State of Wisconsin Medical Examining Board recently held a hearing to consider a proposed rule that, if enacted, would provide the first


The President’s Precision Medicine Initiative - The First Annual Check-Up
  • Foley & Lardner LLP
  • USA
  • January 26 2016

Watching President Obama's recent 2016 State of the Union Address reminded me that one year has passed since the President announced a new


Incomplete Restriction Requirement Stops Clock For Patent Term Adjustment
  • Foley & Lardner LLP
  • USA
  • January 26 2016

In Pfizer v. Lee, the Federal Circuit affirmed the decision of the U.S. District Court for the Eastern District of Virginia that upheld the USPTO's


Executive Gun Control Actions Result in HIPAA Modifications
  • Foley & Lardner LLP
  • USA
  • January 25 2016

In response to the Obama Administration’s executive actions to reduce gun violence, on January 4, 2016, the U.S. Department of Health and Human


PTAB Denies Challenge Of Abbvie Humira Patents
  • Foley & Lardner LLP
  • USA
  • January 19 2016

The USPTO Patent Trial and Appeal Board (PTAB) denied institution of two Inter Partes Review challenges brought by Amgen, Inc. against two Humira


Potential Part B Drug Payment Cuts for 340B Hospitals
  • Foley & Lardner LLP
  • USA
  • January 19 2016

The influential Medicare Payment Advisory Commission (MedPAC) has voted to recommend to Congress in its March report that Medicare Part B drug